Does HPV vaccination actually reduce cervical cancer cases, or only precancer?

The short version: yes, real-world data now show fewer invasive cervical cancers in vaccinated women, but only in the cohorts vaccinated young, and the effect is smaller and less certain than the headlines suggest.

The strongest evidence is a population study from England. Women offered routine HPV vaccination at age 12 to 13 had about 84% fewer invasive cervical cancers than women never offered it, and about 94% fewer cases of CIN3, the highest-grade precancer [4]. The same study estimated 687 cervical cancers prevented by mid-2020 [4]. That is a hard clinical outcome, not an antibody titer, and it is the answer to your question: vaccination reduced actual cancer, not just precancer.

But the benefit shrinks fast with age at vaccination. In catch-up cohorts vaccinated at 16 to 18, CIN3 reduction was about 39%, versus 97% in the 12 to 13 group [5]. A 2026 review of England mortality data found zero cervical cancer deaths in the most-vaccinated 20 to 24 group against about 23 expected, but that comparison was a modeled historical counterfactual, not a real unvaccinated control group [2]. At ages 30 to 34 the mortality estimate was imprecise and included no reduction at all [2].

Two cautions. The English studies are observational, using vaccine offer as a stand-in for actual vaccination, and screening changed over the same period [4][6]. And a modeling paper warns that removing HPV 16 and 18 can let other types fill the niche, potentially inflating apparent benefit by 3 to 10% [3]. Canada shows a real prevention gap: cervical cancer rose in women 35 to 44 from 2001 to 2022 despite vaccination and screening [1].

My call: HPV vaccination does reduce invasive cervical cancer, convincingly in girls vaccinated before sexual debut, weakly or not at all in older catch-up groups. Confidence: moderate.